301015 Qingdao Baheal Medical INC.
- 32.35
- +0.78+2.47%
Qingdao Baheal Medical INC. News
Baiyang Pharmaceutical (301015): Performance is in line with expectations, excellent performance in Q1
Events: 1) The company released its 2023 annual report, achieving operating income of 7.564 billion yuan, an increase of 0.72% over the reporting period; realized net profit of 656 million yuan, an increase of 29.55% over the previous year; 2) The company released 20
Baiyang Pharmaceutical (301015): High growth continues to be optimistic about new momentum
Key investment performance: Brand operations continue to increase, revenue structure continues to be optimized 2023A: Core brand operating revenue of 4.40 billion yuan, YOY +18.91%; of these, Diqiao's revenue is 1,897 billion yuan, YOY+
SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 ann
SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 annual report and 2024 quarterly report, and the profit side achieved rapid growth; 2) sales expenses continued to be optimized, and profitability improved; 3) Continued improvement of the product matrix, and innovative pharmaceutical devices are expected to be realized. (Mainichi Keizai Shimbun)
Baiyang Pharmaceutical (301015): Continued focus on core business, brand operation drives rapid performance growth
Event: The company released its 2023 annual report and 2024 quarterly report, and achieved rapid profit growth. In 2023, the company achieved operating income of 7.564 billion yuan, a year-on-year increase of 0.72%, and net profit of 656 million yuan to mother
Baiyang Pharmaceutical (301015): Committed to building a “brand highway”, profitability is expected to continue to increase
Incident: The company released its annual report for the year 20223 and the quarterly report for 2024. In 2023, it achieved operating income of 7.564 billion yuan (yoy +0.72%) and net profit to mother of 656 million yuan (yoy +30%), deducted
China Galaxy released a research report on April 23 stating that Baiyang Pharmaceutical (301015.SZ) was given a recommended rating. The main reasons for the rating include: 1) focus on core brand operations, and the pharmaceutical business continues to sh
China Galaxy released a research report on April 23 stating that Baiyang Pharmaceutical (301015.SZ) was given a recommended rating. The main reasons for the rating include: 1) focus on core brand operations, and the pharmaceutical business continues to shrink; 2) the Q1 revenue side declined slightly, and the profit side maintained rapid growth; 3) entering the development of cutting-edge domestic innovative pharmaceutical devices and gradually establishing its own innovation incubation platform. (Mainichi Keizai Shimbun)
Baiyang Pharmaceutical (301015.SZ): Plans to jointly invest in partnerships with professional investment institutions
Gelonghui, April 23 | Baiyang Pharmaceutical (301015.SZ) announced that the company collaborates with AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., and Tianjin Jiashan Industrial Development Investment Co., Ltd. Invested in the establishment of AstraZeneca CICC
Baiyang Pharmaceutical (301015.SZ) plans to invest 50 million yuan in AstraZeneca CICC Qingdao Healthcare Venture Capital Fund to invest in the healthcare sector
Baiyang Pharmaceutical (301015.SZ) announced that the company, AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC...
A-share pharmaceutical stocks declined, and many stocks such as Zhifei Biotech fell by more than 10%
Gelonghui, April 23 | Zhifei Biotech, Baiyang Pharmaceutical, Tuoxin Pharmaceutical, and Baicheng Pharmaceutical all fell by more than 10%, while Anke Biotech and Tebao Biotech fell more than 8%.
Baiyang Pharmaceutical (301015): Steady and high growth in performance, actively rewarding investors with a dividend payout rate of 61%
The company released the 2023 annual report and the 2024 quarterly report: achieved revenue of 7.56 billion yuan (yoy +0.72%) in 2023, net profit of 656 million yuan (yoy +29.6%), deducted from the mother
Baiyang Pharmaceutical (301015.SZ): 2023 net profit of 656 million yuan, plans to distribute 10 to 7.62 yuan
Gelonghui, April 22丨Baiyang Pharmaceutical (301015.SZ) announced its 2023 annual report. Operating income for the reporting period was 7.564 billion yuan, up 0.72% year on year; net profit attributable to shareholders of listed companies was 656 million yuan, up 29.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 635 million yuan, up 25.14% year on year; basic income per share was 1.25 yuan; it plans to pay a cash dividend of 7.62 yuan (tax included) for every 10 shares to all shareholders.
Baiyang Pharmaceutical (301015): The CSO industry is developing rapidly, and the company's BD landed as scheduled
The CSO industry is growing rapidly, and the company is on the fast track of growth. 2023 is a year of acceleration in the commercial outsourcing circuit. We have not only observed an acceleration in the streamlining of MNC's sales team and diversified outsourcing, but also observed many domestic companies
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Baiyang Pharmaceutical (301015): CSO entering a period of accelerated platform expansion
Key investment points Core view: Adding its own operating cycle to the industrial cycle brings greater performance flexibility. We believe that Baiyang Pharmaceutical is a CSO company (sales and service outsourcing company) that has proven its ability to build brands and is gradually focusing on brand operation
Baiyang Pharmaceutical (301015): Focus on brand operation business to build a leading domestic CSO
Revenue is growing steadily, and profit margins are increasing year by year. Baiyang Pharmaceutical was founded in 2005. It is a professional pharmaceutical product commercial chemical platform. Its main business is to provide comprehensive marketing services for pharmaceutical product manufacturers, including providing brand operations for pharmaceutical products,
Baiyang Pharmaceutical (301015): Scarce CSO Professional Platform for Win-win Cooperation with Pharmaceutical Companies
As a scarce integrated commercialization platform, Baiyang Pharmaceutical has laid out a four-category matrix, created successful cases in various fields such as OTC, OTX, innovative drugs, and high-end medical devices, and accumulated mature brand experience and expansion, with strong BD capabilities and channels
Baiyang Pharmaceutical (301015.SZ): The Diqiao series in operation is still growing. The Diqiao series has various product standards such as adult calcium, maternal and child calcium, and children's calcium
Gelonghui, January 19 | Baiyang Pharmaceutical (301015.SZ) said on the investor interactive platform that the Diqiao series operated by the company is still growing. The Diqiao series has multiple product regulations such as adult calcium, maternal and child calcium, and children's calcium. At the same time, the company will launch calcium preparations for middle-aged and elderly people in due course according to the business plan; currently, the company has formed a multi-brand matrix with four major categories of OTC, DaHealth, OTX and other prescription drugs, and high-end medical devices.% Reduced to the first three quarters of 2023
Baiyang Pharmaceutical (301015.SZ) subsidiary plans to sell 100% of Beijing Baiyang Zhixin's shares to Baiyang Group to reduce business risk
Baiyang Pharmaceutical (301015.SZ) announced that Beijing Baiyang Zhihe Medical Achievement Transformation Service Co., Ltd., a wholly-owned subsidiary of the company...
Baiyang Pharmaceutical (301015.SZ) plans to spend 49.5 million yuan on joint investment funds with professional investment institutions
Baiyang Pharmaceutical (301015.SZ) issued an announcement to achieve the strategic layout of the industry, seize opportunities for strategic cooperation, and fully...
Baiyang Pharmaceutical (301015): BD can be expected to accelerate annual results
Event description The company released its report for the third quarter of 2023. The third quarter of 2023 achieved revenue of 1,861 million dollars, an increase of 4.03% over the previous year; realized net profit of 192 million yuan, an increase of 49.24% over the previous year; achieved deductions
Analysis
Price Target
No Data
